betadine 100 mg/ml antiseptic paint
mundipharma pharmaceuticals limited - iodinated povidone - cutaneous solution - 100 milligram(s)/millilitre - iodine products; povidone-iodine
betadine alcoholic 100 mg/ml cutaneous solution
mundipharma pharmaceuticals limited - iodinated povidone - cutaneous solution - 100 milligram(s)/millilitre - iodine products; povidone-iodine
standardised betadine antiseptic 100 mg/ml cutaneous solution
mundipharma pharmaceuticals limited - iodinated povidone - cutaneous solution - 100 milligram(s)/millilitre - iodine products; povidone-iodine
braunoderm coloured
b. braun medical limited - povidone-iodine isopropanol - cutaneous solution - 1 %w/v
braunol cutaneous solution 7.5 %w/v
b. braun medical limited - povidone-iodine - cutaneous solution - 7.5 %w/v
braunosan cutaneous solution 7.5 %w/w
b. braun medical limited - povidone-iodine - cutaneous solution - 7.5 %w/w
ark iodine spray
ark animal care ltd - povidone-iodine - cutaneous spray solution - 0.5 %w/v - bovine - antiseptics
noroseal 2.6 g intramammary suspension for cattle
norbrook laboratories (ireland) limited - bismuth subnitrate, heavy - intramammary suspension - 2.6 g/syringe - various products for teats and udder
sureseal 2.6 g intramammary suspension for cattle
norbrook laboratories (ireland) limited - bismuth subnitrate, heavy - intramammary suspension - 2.6 g/syringe - various products for teats and udder
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist.sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.